Allamneni Chaitanya, Alkurdi Basem, Naseemuddin Rehan, McGuire Brendan M, Shoreibah Mohamed G, Eckhoff Devin E, Peter Shajan
aDepartment of Medicine, Division of Gastroenterology and Hepatology bDepartment of Surgery, Division of Transplant Surgery cDepartment of Internal Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Eur J Gastroenterol Hepatol. 2017 Aug;29(8):973-976. doi: 10.1097/MEG.0000000000000908.
Gastric antral vascular ectasia (GAVE) is an important cause of upper gastrointestinal bleeding and anemia in patients with cirrhosis. The aim of our study was to evaluate the effect of orthotopic liver transplantation (OLT) on GAVE and associated anemia.
We performed a chart review and identified all cirrhotic patients with GAVE who underwent OLT at the University Of Alabama at Birmingham between 2005 and 2013. Population's demographics, etiology of cirrhosis, comorbidities, presentation and treatment modalities of GAVE, endoscopic and histopathologic reports, hemoglobin values before and after transplant, and immunosuppressive regimens were collected.
Twelve patients were identified, mean age 52.4±4.4 years; seven were men (58.3%); 11 (91.7%) were White; and 6 of 12 patients had biopsy-proven GAVE. The most common etiology of cirrhosis in the cohort was chronic hepatitis C and obesity was the most common chronic condition in 50 and 83.3%, respectively. Anemia resolution was observed in 9/12 (75%) patients who underwent OLT with an increase in hemoglobin from 8.1±2.4 (5.7-13.1) before transplant to 12.0±1.4 (10-15) after transplant (P<0.0001). Esophagogastroduodenoscopy after transplant was performed in all 12 (100%) patients. The mean time between transplant and post-OLT esophagogastroduodenoscopy was 13.8±18.28 (2-57) months; complete resolution of GAVE was observed in 10 (83.3%) patients, with resolving GAVE in one (8.3%) patient.
GAVE is an important cause of anemia and upper gastrointestinal bleeding in patients with liver cirrhosis. Our findings show that liver transplantation can resolve GAVE and related anemia.
胃窦血管扩张症(GAVE)是肝硬化患者上消化道出血和贫血的重要原因。本研究的目的是评估原位肝移植(OLT)对GAVE及相关贫血的影响。
我们进行了一项病历回顾,确定了2005年至2013年间在阿拉巴马大学伯明翰分校接受OLT的所有患有GAVE的肝硬化患者。收集了患者的人口统计学资料、肝硬化病因、合并症、GAVE的表现及治疗方式、内镜和组织病理学报告、移植前后的血红蛋白值以及免疫抑制方案。
共确定了12例患者,平均年龄52.4±4.4岁;7例为男性(58.3%);11例(91.7%)为白人;12例患者中有6例经活检证实患有GAVE。该队列中肝硬化最常见的病因是慢性丙型肝炎,50%和83.3%的患者中最常见的慢性病分别是肥胖。接受OLT的12例患者中有9例(75%)贫血得到缓解,血红蛋白从移植前的8.1±2.4(5.7 - 13.1)升至移植后的12.0±1.4(10 - 15)(P<0.0001)。所有12例(100%)患者移植后均接受了食管胃十二指肠镜检查。移植与OLT后食管胃十二指肠镜检查的平均时间为13.8±18.28(2 - 57)个月;10例(83.3%)患者GAVE完全缓解,1例(8.3%)患者GAVE有所缓解。
GAVE是肝硬化患者贫血和上消化道出血的重要原因。我们的研究结果表明,肝移植可以缓解GAVE及相关贫血。